The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Targeting hepcidin in polycythemia vera and myelofibrosis
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the evolving understanding of iron regulation and hepcidin biology in myeloproliferative neoplasms (MPNs), highlighting the role of hepcidin in both myelofibrosis and polycythemia vera (PV). Dr Mesa notes that modulating hepcidin levels may help alleviate anemia in myelofibrosis and reduce phlebotomy requirements in PV, potentially improving symptom control and disease management. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
